

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <http://orca.cf.ac.uk/121317/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Scott Roberts, Mary, Gafni, Rachel I, Brillante, Beth, Guthrie, Lori C, Streit, Jamie, Gash, David, Gelb, Jeff, Krusinska, Eva, Brennan, Sarah C, Schepelmann, Martin, Riccardi, Daniela, Ezuan Bin Khayat, Mohd, Ward, Donald T, Nemeth, Edward F, Rosskamp, Ralf and Collins, Michael T 2019. Treatment of autosomal dominant hypocalcemia Type 1 with the calcilytic NPSP795 (SHP635). *Journal of Bone and Mineral Research* 34 (9) , pp. 1609-1618. 10.1002/jbmr.3747 filefilefilefilefile

Publishers page: <https://doi.org/10.1002/jbmr.3747> <<https://doi.org/10.1002/jbmr.3747>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



## **SUPPLEMENTAL MATERIAL**

### **Treatment of Autosomal Dominant Hypocalcemia Type 1 with the Calcilytic NPSP795**

**(SHP635)**


Mary Scott Roberts, Rachel I. Gafni, Beth Brillante, Lori C. Guthrie, David Gash, Jeff Gelb, Eva Krusinska, Sarah C. Brennan, Martin Schepelmann, Daniela Riccardi, Mohd Ezuan Bin Khayat, Donald T. Ward, Edward F. Nemeth, Ralf Roskamp, and Michael T. Collins

#### Table of Contents:

- Supplemental figures
- Supplemental tables

## Supplemental Figures


Supplemental Figure 1



### Supplemental Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.


A total of 9 subjects were screened for the study. Only 5 subjects were enrolled in the study, as 1 subject did not meet the study entry criteria and the study was closed after 5 subjects had been enrolled. Of the 5 subjects, all completed the study as per the protocol. All subjects received the study drug and were included in the safety analysis set, pharmacokinetics (PK) analysis set and pharmacodynamics (PD) analysis set.

Supplemental Figure 2




**Supplemental Figure 2. Half-maximal activation (EC<sub>50</sub>) for extracellular calcium in an *in vitro* model of wild type (WT) and mutant calcium sensing receptors (CaRs) and response to NPSP795.** All mutant CaRs had an EC<sub>50</sub> at lower concentrations of extracellular calcium compared to WT CaR (A). Treatment with NPSP795 increased the EC<sub>50</sub> for all CaR mutants. A representative concentration-response curve for the A840V mutation (C) shows an increase in the EC<sub>50</sub> towards that of the WT CaR (B) with NPSP795 treatment. n = number of experiments

Supplemental Figure 3



**Supplemental Figure 3. Effects of NPSP795 (SHP635) on extracellular calcium-induced ERK and p38<sup>MAPK</sup> phosphorylation in an *in vitro* model of wild type (WT) and mutant calcium-sensing receptors (CaRs).** Extracellular calcium-induced ERK phosphorylation was enhanced in CaR mutants (A). All mutant CaRs had an EC<sub>50</sub> at lower concentrations of extracellular calcium compared to WT CaR. NPSP795 treatment inhibited the enhanced ERK phosphorylation present in mutant CaRs (B). Extracellular calcium-induced p38<sup>MAPK</sup> phosphorylation was enhanced in CaR mutants (C). All mutant CaRs had an EC<sub>50</sub> at lower concentrations of extracellular calcium compared to WT CaR. NPSP795 treatment inhibited the enhanced p38<sup>MAPK</sup> phosphorylation present in mutant CaRs (D). Statistical analysis was performed using one-way ANOVA and Dunnett's post-test between log EC<sub>50</sub> of mutant CaRs vs. WT. n = number of experiments. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001

## Supplemental Figure 4



### Supplemental Figure 4. Effect of ADH mutations on CaSR total and surface expression.

HEK293 cells were transiently transfected with FLAG-tagged wt or mutant construct before being fixed and probed with anti-FLAG antibody to measure total (blue) or cell surface expression (red). Results were obtained in Flp-In293 cells transfected with vector alone were used for background subtraction and mutants were normalised to the level of total wt CaR expression. In the transient overexpression system, there are no significant differences between wt CaR and the 5 ADH1 mutants at either the total or surface expression level (2-way ANOVA, comparison between rows,  $p > 0.05$ ). Data shown as mean  $\pm$  SEM.

## Supplemental Tables

**Supplemental Table 1. Primers used for generation of ADH mutations.**

Mutation	Nucleotide change	Direction	Sequence
Q245R	734A>G	Fwd	GAA CTC ATC TCC CGG TAC TCT GAT GAG G
		Rev	CCT CAT CAG AGT ACC GGG AGA TGA GTT C
E228K	682G>A	Fwd	GAT TGA GAA ATT CCG AAA GGA AGC TGA GGA AAG
		Rev	CTT TCC TCA GCT TCC TTT CGG AAT TTC TCA ATC
A840V	2519C>T	Fwd	GTA GAG GTG ATT GTC ATC CTG GCA GCC
		Rev	GGC TGC CAG GAT GAC AAT CAC CTC TAC
E228A	683A>C	Fwd	GAT TGA GAA ATT CCG AGC GGA AGC TGA GGA AAG G
		Rev	CCT TTC CTC AGC TTC CGC TCG GAA TTT CTC AAT C

**Supplemental Table 2. Elemental calcium administered to subjects as supplement/rescue (mg)**

Patient #	1	2	3	4	5
CaR Mutation	A840V	Q245R	E228K	A840V	E228A
<u>Supplement</u>					
Day 1			1200	250	
Day 2		1200	1200	250	600
Day 3	600	1200	1200	250	600
Day 4	1200	1200	1200	250	600
<u>Rescue</u>					
Day 1					
Day 2		600	1800		
Day 3					
Day 4					